Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation

Liver Transplantation

Volumn 21, Issue 2, 2015, Pages 248-257

  Terzi, Eleonora ^a,b   Kim, W Ray ^b   Sanchez, William ^b   Charlton, Michael R ^b   Schmeltzer, Paul ^b   Gores, Gregory J ^b   Andrews, James C ^b   Smyrk, Thomas C ^b   Heimbach, Julie K ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MITOMYCIN;

ADULT; AGED; ARTICLE; ASCITES; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOEMBOLIZATION; DRUG DOSE REDUCTION; EXPLANT; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE RISK; RETREATMENT; SURVIVAL RATE; TREATMENT INDICATION; TUMOR NECROSIS; ARTERY; CARCINOMA, HEPATOCELLULAR; FOLLOW UP; LIVER; LIVER NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NECROSIS; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; ARTERIES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NECROSIS; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84921787659     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24041     Document Type: Article

References (18)

1. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
2. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A; for OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012;13:e11-e22.
3. Goldberg D, French B, Abt P, Feng S, Cameron AM. Increasing disparity in waitlist mortality rates with increased Model for End-Stage Liver Disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma. Liver Transpl 2012;18:434-443.
4. Massie AB, Caffo B, Gentry SE, Hall EC, Axelrod DA, Lentine KL, et al. MELD exceptions and rates of waiting list outcomes. Am J Transplant 2011;11:2362-2371.
5. Washburn K, Edwards E, Harper A, Freeman R. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant 2010;10:1643-1648.
6. Cescon M, Cucchetti A, Ravaioli M, Pinna AD. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J Hepatol 2013;58:609-618.
7. Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 2013;266:376-382.
8. Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002;50:123-128.
9. Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010;16:262-278.
10. Ravaioli M, Grazi GL, Ercolani G, Fiorentino M, Cescon M, Golfieri R, et al. Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation 2004;78:1780-1786.
11. Schaudt A, Kriener S, Schwarz W, Wullstein C, Zangos S, Vogl T, et al. Role of transarterial chemoembolization for hepatocellular carcinoma before liver transplantation with special consideration of tumor necrosis. Clin Transplant 2009;23(suppl 21):61-67.
12. Bruix J, Sherman M; for Practice Guidelines Committee of the American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
13. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al.; for EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430.
14. Dabbs DJ, Geisinger KR, Ruggiero F, Raab SS, Nalesnik M, Silverman JF; for Association of Directors of Anatomic and Surgical Pathology. Recommendations for the reporting of tissues removed as part of the surgical treatment of malignant liver tumors. Hum Pathol 2004;35:1315-1323.
15. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954;7:462-503.
16. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943.
17. Alberts SR, Gores GJ, Kim GP, Roberts LR, Kendrick ML, Rosen CB, et al. Treatment options for hepatobiliary and pancreatic cancer. Mayo Clin Proc 2007;82:628-637.
18. Golfieri R, Cappelli A, Cucchetti A, Piscaglia F, Carpenzano M, Peri E, et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology 2011;53:1580-1589.